March 15, 2018 – A newly-designed wristband and corresponding app that works with a smartwatch can accurately display ...
March 15, 2018 — For people with heart failure, getting a seasonal influenza (flu) vaccine in a given year was ...
March 15, 2018 — Women with normal blood pressure during pregnancy and who breastfed their babies for at least six ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 15, 2018 — Women diagnosed with preeclampsia during pregnancy were significantly more likely to develop high blood ...
March 14, 2018 — A late-breaking analysis of the landmark COMPASS study presented at the American College of Cardiology ...
The Zoll LifeVest is a temporary, wearable defibrillator designed as a safety net for patients, especially those being ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
After six months of follow-up, women newly diagnosed with breast cancer who were given the beta blocker carvedilol to prevent heart issues while undergoing chemotherapy showed no difference in declines in heart function compared with those taking a placebo. Patients who took carvedilol, however, were significantly less likely to have an elevated marker in the blood that signals injury to the heart, according to a study being presented at the American College of Cardiology’s (ACC) 67th Annual Scientific Session, March 10-12 in Orlando, Fla.
March 14, 2018 — Breast cancer patients who started taking one of two well-known heart medications at the same time they ...
March 13, 2018 – Among patients with persistently high cholesterol despite high-intensity statin therapy, the proprotein ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
March 13, 2018 – Wearing a lightweight vest equipped with a cardioverter defibrillator that detects abnormal heart ...
March 13, 2018 – HeartFlow, Inc. today announced that it has entered into a licensing and technology transfer agreement ...
March 13, 2018 – Infraredx, a company that works in intravascular imaging for mapping coronary artery disease, today ...
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
At the American College of Cardiology’s (ACC) 67th Annual Scientific Session and Expo, March 10-12 in Orlando, Fla., Siemens Healthineers launched its new portable cardiovascular ultrasound solution, the Acuson Bonsai.
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully implantable within the chest experienced no malfunctions requiring replacement or removal of the device for blood clotting. Further, their risk of a stroke was halved compared with patients who received the established version of the pump that requires an abdominal location for the implant, according to research presented at the American College of Cardiology’s 67th Annual Scientific Session, March 10-12 in Orlando, Fla.
Medtronic plc unveiled outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world NOTION trial (Nordic Aortic Valve Intervention Trial) at the American College of Cardiology (ACC) 67th Annual Scientific Sessions, March 10-12, 2018, in Orlando Fla. Both studies examined patients with the CoreValve transcatheter aortic valve replacement (TAVR) system at five years post-implant. Results from the studies demonstrated that patients implanted with the CoreValve TAVR system showed strong hemodynamic performance and improved quality of life out to five years.